Rockwell Medical's SFP Phase IIb data accepted for presentation at XLVII ERA-EDTA Congress

NewsGuard 100/100 Score

Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that Phase IIb data for its lead drug candidate Soluble Ferric Pyrophosphate (SFP) have been accepted for presentation at the XLVII European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress, organized in collaboration with the Deutsche Gesellschaft fur Nephrologie (DGfN) in Munich, Germany, June 25-28, 2010.

The SFP Phase IIb data were submitted as a late-breaking clinical trial abstract.  The acceptance of the abstract for the meeting is noteworthy, as only significant clinical trials of extraordinary importance are considered for presentation. 

Phase IIb data will be presented during the ERA-EDTA meeting for Rockwell's investigational drug SFP, which is being studied as an iron replacement product for maintaining hemoglobin in the target range while reducing erythropoiesis stimulating agent (ESA) dosage in adult hemodialysis-dependent chronic kidney disease (CKD-HD) patients.  The data will be presented in the poster area of the International Congress Centre Munich on June 26, 2010, number Sa681.  Dr. Ajay Gupta, Chief Scientific Officer, and Dr. Richard Yocum, VP of Drug Development, will be present throughout the two official poster sessions from 10:30 to 11:15 hrs. and from 16:15 to 17:00 hrs.  

"We are looking forward to sharing this SFP data at the ERA-EDTA meeting in June," stated Dr. Richard Yocum, VP of Clinical Development at Rockwell.  "We are focused on bringing SFP, a novel continuous iron maintenance therapy, to the worldwide ESRD patient population.  After our upcoming meeting with the FDA, we hope to initiate our Phase III clinical program in the second-half of this year."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Gene therapy and glycoside drugs offer new hope for polycystic kidney disease treatment